Calithera Biosciences (CALA) Issues Earnings Results

Calithera Biosciences (NASDAQ:CALA) released its quarterly earnings results on Wednesday. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.12), Fidelity Earnings reports. Calithera Biosciences had a negative net margin of 90.65% and a negative return on equity of 22.09%.

Calithera Biosciences stock opened at $4.90 on Friday. Calithera Biosciences has a 52 week low of $4.05 and a 52 week high of $16.50. The company has a market cap of $181.02 million, a price-to-earnings ratio of -5.83 and a beta of 2.35.

Several research firms have commented on CALA. ValuEngine raised shares of Calithera Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Zacks Investment Research cut shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 24th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. Calithera Biosciences currently has a consensus rating of “Hold” and an average target price of $9.88.

An institutional investor recently raised its position in Calithera Biosciences stock. Bank of New York Mellon Corp grew its position in shares of Calithera Biosciences Inc (NASDAQ:CALA) by 17.7% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 161,982 shares of the biotechnology company’s stock after buying an additional 24,343 shares during the quarter. Bank of New York Mellon Corp owned 0.45% of Calithera Biosciences worth $810,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 54.87% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by WKRB News and is the property of of WKRB News. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at

Calithera Biosciences Company Profile

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.

Featured Article: Yield Curve

Earnings History for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with's FREE daily email newsletter.

Leave a Reply